Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis

Health and Quality of Life Outcomes

Volumn 6, Issue , 2008, Pages

  Ziemssen, Tjalf ^a   Hoffman, Josef ^a   Apfel, Rainer ^b   Kern, Simone ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b TEVA Germany ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLATIRAMER; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; PEPTIDE;

ABSENTEEISM; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; HUMAN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RATING SCALE; RELAPSE; SCORING SYSTEM; TACHYCARDIA; TREATMENT DURATION; VISUAL ANALOG SCALE; WELLBEING; CLASSIFICATION; DISABILITY; EVALUATION; GERMANY; OBSERVATION; QUESTIONNAIRE; SICKNESS IMPACT PROFILE; TREATMENT OUTCOME;

ABSENTEEISM; ADULT; DISABILITY EVALUATION; FATIGUE; FEMALE; GERMANY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OBSERVATION; PEPTIDES; PROSPECTIVE STUDIES; QUESTIONNAIRES; SICKNESS IMPACT PROFILE; TREATMENT OUTCOME;

EID: 52449091605     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-6-67     Document Type: Article

References (36)

1. Krupp LB Pollina DA: Mechanisms and management of fatigue in progressive neurological disorders. Current opinion in neurology 1996, 9(6):456-460. 10.1097/00019052-199612000-00011 9007405
2. Fisk JD Pontefract A Ritvo PG Archibald CJ Murray TJ: The impact of fatigue on patients with multiple sclerosis. The Canadian journal of neurological sciences 1994, 21(1):9-14. 8180914
3. Freal JE Kraft GH Coryell JK; Symptomatic fatigue in multiple sclerosis. Arch Phys Med Rehabil 1984, 65(3):135-138. 6703889
4. Vercoulen JH Hommes OR Swanink CM Jongen PJ Fennis JF Galama JM Meer van der JW Bleijenberg G: The measurement of fatigue in patients with multiple sclerosis. A multidimensional comparison with patients with chronic fatigue syndrome and healthy subjects. Archives of neurology 1996, 53(7):642-649. 8929171
5. Schwid SR Covington M Segal BM Goodman AD: Fatigue in multiple sclerosis: Current understanding and future directions. J Rehabil Res Dev 2002, 39(2):211-224. 12051465
6. Amato MP Ponziani G Rossi F Liedl CL Stefanile C Rossi L: Quality of life in multiple sclerosis: The impact of depression, fatigue and disability. Multiple sclerosis (Houndmills, Basingstoke, England) 2001, 7(5):340-344. 11724451
7. Janardhan V Bakshi R: Quality of life in patients with multiple sclerosis: The impact of fatigue and depression. Journal of the neurological sciences 2002, 205(1):51-58. 10.1016/S0022-510X(02)00312-X 12409184
8. Lobentanz IS Asenbaum S Vass K Sauter C Klosch G Kollegger H Kristoferitsch W Zeitlhofer J: Factors influencing quality of life in multiple sclerosis patients: Disability, depressive mood, fatigue and sleep quality. Acta neurologica Scandinavica 2004, 110(1):6-13. 10.1111/ j.1600-0404.2004.00257.x 15180801
9. Flachenecker P Kumpfel T Kallmann B Gottschalk M Grauer O Rieckmann P Trenkwalder C Toyka KV: FAtigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters. Multiple sclerosis (Houndmills, Basingstoke, England) 2002, 8(6):523-526. 10.1191/ 1352458502ms839oa 12474995
10. Tellez N Rio J Tintore M Nos C Galan I Montalban X: Does the Modified Fatigue Impact Scale offer a more comprehensive assessment of fatigue in MS?. Multiple sclerosis (Houndmills, Basingstoke, England) 2005, 11(2):198-202. 10.1191/1352458505ms1148oa 15794395
11. Jackson MF Quaal C Reeves MA: Effects of multiple sclerosis on occupational and career patterns. Axone (Dartmouth, NS) 1991, 13(1):16-17. 20-12.
12. Smith MM Arnett PA: Factors related to employment status changes in individuals with multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England) 2005. 11(5):602-609. 10.1191/1352458505ms1204oa 16193900
13. Comi G Leocani L Rossi P Colombo B: Physiopathology and treatment of fatigue in multiple sclerosis. Journal of neurology 2001, 248(3):174-179. 10.1007/s004150170222 11355149
14. Krupp LB: Fatigue in multDple sclerosis: definition, pathophysiology and treatment. CNS drugs 2003, 17(4):225-234. 10.2165/ 00023210-200317040-00002 12665396
15. Kesselring J Thompson AJ; Spasticity, ataxia and fatigue in multiple sclerosis. Bailliere's clinical neurology 1997, 6(3):429-445. 10101582
16. Kern S Ziemssen T: Brain immune communication psychoneuroimmunology of multiple sclerosis. Mult Scler 2007. 17881389
17. Zifko UA: Management of fatigue in patients with multiple sclerosis. Drugs 2004, 649(12):1295-1304. 10.2165/00003495-200464120-00003 15200345
18. Pucci E Branas P D'Amico R Giuliani G Solari A Taus C: Amantadine for fatigue in multiple sclerosis. Cochrane database of systematic reviews (Online) 2007:CD002818 17253480
19. Rammohan KW Rosenberg JH Lynn DJ Blumenfeld AM Pollak CP Nagaraja HN: Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: A two centre phase 2 study. Journal of neurology, neurosurgery, and psychiatry 2002, 72(2):179-183. 1737733 11796766 10.1136/jnnp.72.2.179
20. Stankoff B Waubant E Confavreux C Edan G Debouverie M Rumbach L Moreau T Pelletier J Lubetzki C Alanet M: Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology 2005, 64(7):1139-1143. 15824337
21. Corboy JR Goodin DS Frohman EM: Disease-modifying Therapies for Multiple Sclerosis. Current treatment options in neurology 2003, 5(1):35-54. 10.1007/s11940-003-0021-0 12521562
22. Metz LM Patten SB Archibald CJ Bakker JI Harris CJ Patry DG Bell RB Yeung M Murphy WF et al. Stoian CA: The effect of immunomodulatory treatment on multiple sclerosis fatigue Journal of neurology, neurosurgery, and psychiatry 2004, 75(7):1045-1047. 1739126 15201369 10.1136/jnnp.2002.007724
23. McDonald WI Compston A Edan G Goodkin D Hartung HP Lublin FD McFarland HF Paty DW Polman CH Reingold SC et al.: Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Annals of neurology 2001, 50(1):121-127. 10.1002/ana.1032 11456302
24. Kurtzke JF: Rating neurologic impairment in muAtiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33(11):1444-1452. 6685237
25. Multiple Sclerosis Council for Clinical Practice: Guidelines Fatigue and multiple sclerosis: Evidence-based management strategies for fatigue in multiple sclerosis Washington DC: Paralyzed Veterans of America 1998:1-33
26. Heesen C Nawrath L Reich C Bauer N Schulz KH Gold SM: Fatigue in multiple sclerosis: An example of cytokine mediated sickness behaviour?. Journal of neurology, neurosurgery, and psychiatry 2006, 77(1):34-39. 10.1136/jnnp.2005.065805 16361589
27. Flachenecker P Bihler I Weber F Gottschalk M Toyka KV Rieckmann P: Cytokine mRNA expression in patients with multiple sclerosis and fatigue. Multiple sclerosis (Houndmills, Basingstoke, England) 2004, 10(2):165-169. 10.1191/1352458504ms991oa 15124762
28. Ziemssen T Kumpfel T Klinkert WE Neuhaus O Hohlfeld R: Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain 2002, 125(Pt 11):2381-2391. 10.1093/brain/awf252 12390966
29. Ziemssen T Reichmann H: Non-motor dysfunction in Parkinson's disease. Parkinsonism & related disorders 2007, 13(6):323-332. 10.1016/ j.parkreldis.2006.12.014 17349813
30. Tartaglia MC Narayanan S Francis SJ Santos AC De Stefano N Lapierre Y Arnold DL: The relationship between diffuse axonal damage and fatigue in multiple sclerosis. Archives of neurology 2004, 61(2):201-207. 10.1001/ archneur.61.2.201 14967766
31. Tedeschi G Dinacci D Lavorgna L Prinster A Savettieri G Quattrone A Livrea P Messina C Reggio A Servillo G: Correlation between fatigue and brain atrophy and lesion load in multiple sclerosis patients independent of disability. Journal of the neurological sciences 2007, 263(1-2):15-19. 10.1016/j.jns.2007.07.004 17673234
32. Rocca MA Agosta F Colombo B Mezzapesa DM Falini A Comi G Filippi M: FMRI changes in relapsing-remitting multiple sclerosis patients complaining of fatigue after IFNbeta-1a injection. Human brain mapping 2007, 28(5):373-382. 10.1002/hbm.20279 16933299
33. Khan O Mackenzie M Shen Y Zak I Latif Z Caon C: Combined Brain MTR and H-MRS Multi-Modality Approach To Investigate Mechanism of Action of Interferon Beta and Glatiramer Acetate in RRMS. Neurology 2007. 17548572
34. Khan O Shen Y Bao F Caon C Tselis A Latif Z Zak I: Long-Term Study of Brain (1)H-MRS Study in Multiple Sclerosis: Effect of Glatiramer Acetate Therapy on Axonal Metabolic Function and Feasibility of Long-Term (1)H-MRS Monitoring in Multiple Sclerosis J Neuroimaging 2007.
35. Lage MJ Castelli-Haley J Oleen-Burkey MA: Effect of immunomodulatory therapy and other factors on employment loss time in multiple sclerosis. Work (Reading, Mass) 2006. 27(2):143-151. 16971761
36. Ziemssen T Neuhaus O Hohlfeld R: Risk-benefit assessment of glatiramer acetate in multiple sclerosis. Drug Saf 2001, 24(13):979-990. 10.2165/ 00002018-200124130-00005 11735654